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Disease activity score (DAS-
28)Abstract Background: The incidence of metabolic syndrome (MetS) increases in rheumatoid
arthritis (RA) patients which increases the risk of cardiovascular disease (CVD). Angiopoietin-2
levels increase in RA and were reported to predict CVD.
Aim of the work: To assess the level of angiopoietin-2 in RA patients and study its relation to
disease activity and its role in those with MetS.
Patients and methods: The study included 80 RA patients (67 females and 13 males) and 20
healthy age and sex matched controls. The patients were divided into Group 1 (n= 40) with
MetS and Group 2 (n= 40) without. Data were collected throughout history, basic clinical exam-
ination and investigation. Disease activity score (DAS-28) was assessed in all patients. Enzyme
linked immunosorbent assay was used for the estimation of angiopoietin-2.
Results: The age and disease duration of those with MetS (40.7 ± 7.23 years and
9.63 ± 6.73 years respectively) and those without (38.6 ± 9.2 and 8.65 ± 5.52 years respectively)
were comparable (p= 0.26 and p= 0.48 respectively). The disease activity (DAS-28) was also simi-
lar in both groups (5.12 ± 0.77 and 5.01 ± 0.96 respectively; p= 0.56). There was a signiﬁcant
increase in the angiopoietin-2 levels in RA patients with MetS (5.31 ± 0.56 ng/ml) than those with-
out (4.93 ± 0.44 ng/ml) (p< 0.001). The levels were signiﬁcantly higher than those of the control
(4.44 ± 0.29 ng/ml) (p< 0.001). The angiopoietin-2 level signiﬁcantly correlated with the DAS-28
(r= 0.23, p= 0.045), systolic (r= 0.36, p= 0.001) and diastolic blood pressure (r= 0.35,
p= 0.001), fasting blood sugar (r= 0.29, p= 0.009) and triglycerides (r= 0.24, p= 0.03).
10 A.H.A.H. Ghazaly et al.Conclusions: Angiopoietin-2 can be used as a biomarker of MetS and disease activity in RA
patients. This could point to those RA patients at risk of developing CVDs.
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licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis is a chronic, systemic, immune-mediated
inﬂammatory disease that affects twice as many women as
men. They have a reduced life expectancy and higher mortality
rates than the general population, with cardiovascular disease
(CVD) accounting for approximately 50% [1]. Although tradi-
tional cardiovascular risk factors such as hypertension, central
obesity and insulin resistance may occur more frequently
among RA patients, this does not fully account for the rates
of CVD observed [2]. Besides genetic predisposition, novel risk
factors and mechanisms, including systemic inﬂammation per
se, have also been implicated [1,3–5]. Several mediators and
factors were reported to play a role in RA patients including
oxidative stress [6–8], osteoprotegerin [9], leptin [10] and
cytokines [11–13].
In another group of Egyptian RA patients, reduced glu-
cose-6 phosphate dehydrogenase (G6PD) activity not only
does not protect against MetS, but may even be considered a
risk factor for its development [14].
In RA, pro-inﬂammatory cytokines and chemokines, pro-
duced by several cell types, induce ongoing recruitment of
immune cells. Inﬂammation is often accompanied by imbal-
anced angiogenesis, and hypoxia is a common stimulus for
both processes [15].
The metabolic syndrome (MetS) describes a constellation of
major risk factors for CVDs such as atherogenic dyslipi-
daemia, obesity, hypertension and diabetes. These associated
risk factors have been previously called syndrome-X or the
insulin resistance syndrome [16]. The National Cholesterol
Education Program’s Adult Treatment Panel III report (ATP
III) identiﬁed the MetS as a multiplex risk factor for CVD that
deserves more clinical attention. [17]. It was reported that the
MetS accounted for 25% of all new-onset CVD [18].
In different rheumatic diseases, MetS played a central role.
It was reported to form an important marker for gout patients
who develop more punched-out erosions [19]. In systemic
lupus erythematosus patients, insulin sensitivity and carotid
intima-media thickness were altered, especially those with
MetS comorbidity with an associated increase in disease activ-
ity and damage [20,21]. In another study on Egyptian RA
patients, IR signiﬁcantly correlated with both disease activity
and duration which pointed out to a signiﬁcant association
with subclinical atherosclerosis [22]. Subclinical atherosclerosis
in RA patients was reported [23].
The angiopoietins are protein growth factors that promote
angiogenesis [24]. Angiopoietin-2 is a major factor in endothe-
lial activation which causes vascular destabilization, thereby
rendering the endothelium responsive to stimulation by inﬂam-
matory and angiogenic cytokines. Angiopoietin-2 was highly
expressed in the synovial membrane of early RA patients
and was rapidly released by proinﬂammatory stimuli, hypoxia,
shear stress and vascular endothelia growth factor (VEGF).Angiopoietin-2 was shown to induce oedema formation in
the mouse paw in an animal model [25].2. Patients and methods
This study was carried out on 80 RA cases diagnosed accord-
ing to ACR criteria of rheumatoid arthritis [26] and 20 age and
sex matched controls, selected from those attending the outpa-
tient Rheumatology clinic of the Sayed Galal hospital, Al
Azhar University during the period from April 2011 to April
2013.The study was approved by the local ethics committee
and consent from the patients was taken before being enrolled
in the study.
Eighty patients were divided into two groups; Group 1
(n= 40) RA patients associated with MetS. Metabolic syn-
drome (MetS) was deﬁned according to adult treatment panel
III (ATPIII) criteria [27] Group 2 (n= 40) RA patients with-
out MetS. Patients with an age <18 years, pregnant, malig-
nancy, psoriasis, or with liver or renal diseases were excluded.
Full history was taken from the patients. Clinical examina-
tion included general, systemic and locomotor systems. DAS28
were calculated for all patients [28]. Laboratory investigations
were performed including complete blood count (CBC),
Erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), Rheumatoid factor (RF), Fasting blood glucose, lipid
proﬁle including cholesterol, Triglyceride (TG), high density
lipoprotein (HDL), low density lipoprotein (LDL), liver func-
tion tests including alanine transaminase (ALT), aspartate
transaminase (AST), renal function tests including blood urea
nitrogen (BUN) and creatinine.
Angiopoietin-2 was assessed in both patients and control by
ELISA (Enzyme-linked immuno sorbent assay) Dia-Sorin,
Italy. This assay employs the quantitative sandwich enzyme
immunoassay technique. A monoclonal antibody speciﬁc for
angiopoietin-2 (ANG-II) has been pre-coated onto a micro
plate. Standards and samples are pipetted into the wells and
any ANG-II present is bound by the immobilized antibody.
After washing away any unbound substances, an enzyme-
linked polyclonal antibody speciﬁc for ANG-II is added to
the wells. Following a wash to remove any unbound anti-
body-enzyme reagent, a TMP substrate solution is added to
the wells and colour develops in proportion to the amount
of ANG-II bound in the initial step. Colour development is
stopped, the intensity of the colour is measured by Elx800 elisa
reader at 450 nm and the standard curve was used to determine
samples’ concentrations.
3. Results
Eighty RA patients were recruited. The age and disease
duration of those with MetS (40.7 ± 7.23 years and 9.63 ±
6.73 years respectively) and those without (38.6 ± 9.2 years
Figure 2 The ROC curve for angiopoietin-2 in patients and
control.
Table 1 Correlation of angiopoietin-2 with various clinical
and laboratory parameters of rheumatoid arthritis patients
(n= 80).
Parameter r (p) Serum angiopoietin-2 (ng/ml)
Age (years) 0.21 (0.06)
Disease duration (years) 0.04 (0.75)
Systolic BP (mmHg) 0.36 (0.001*)
Diastolic BP (mmHg) 0.35 (0.001*)
Waist circumference (cm) 0.19 (0.09)
Tender joint count 0.12 (0.27)
Swollen joint count 0.07 (0.52)
DAS-28 0.23 (0.045*)
ESR (mm/1st h) 0.12 (0.28)
C-reactive protein (mg/dl) 0.18 (0.12)
Fasting blood sugar (mg/dl) 0.29 (0.009*)
Cholesterol (mg/dl) 0.18 (0.11)
Triglycerides (mg/dl) 0.24 (0.03*)
High density lipoprotein (mg/dl) 0.02 (0.86)
Low density lipoprotein (mg/dl) 0.13 (0.26)
Alanine transaminase (IU/L) 0.05 (0.69)
Aspartate transaminase (IU/L) 0.04 (0.7)
Angiopoietin-2 as a biomarker for disease activity 11and 8.65 ± 5.52 years respectively) were comparable (p= 0.26
and p= 0.48 respectively). In those without MetS there were 6
males and 34 females, and in those with MetS were 7 males and
33 females. The disease activity (DAS-28) was also similar in
both groups (5.12 ± 0.77 and 5.01 ± 0.96 respectively;
p= 0.56). There were 20 age and sex matched controls (mean
age 37.7 ± 6.36 years; 6 males and 14 females).
The levels of angiopoietin-2 were signiﬁcantly higher in
the patients (5.12 ± 0.53 ng/ml) compared to the controls
(4.44 ± 0.29 ng/ml) (p< 0.001). The level was signiﬁcantly
higher in those with MetS (5.31 ± 0.56 ng/ml) compared to
those without (4.93 ± 0.44 ng/ml) (p< 0.001). Both groups
were signiﬁcantly higher than levels of the controls (p<
0.001) (Fig. 1).
The Receiver operating characteristic (ROC) curve for
angiopoietin-2 was plotted (Fig. 2) showing a cut off value
of >4.6 ng/ml, sensitivity of 87.5% and a speciﬁcity of 80%.
Correlations of the serum angiopoietin-2 levels in patients with
the different clinical and laboratory parameters are presented
in Table 1. Figure 3 shows the correlation of angiopoietin-2
with DAS28.
4. Discussion
Rheumatoid arthritis (RA) is an autoimmune chronic, sys-
temic inﬂammatory disorder that may affect many tissues
and organs, but principally attacks synovial joints. It can be
a disabling and painful condition, which can lead to substan-
tial loss of functioning and mobility if not adequately treated
[29]. People with RA are more prone to atherosclerosis, and
risk of myocardial infarction (heart attack) and stroke is mark-
edly increased [30]. Cardiovascular (CVD) mortality is
increased in RA, with standardized mortality rates of 1.13–
5.15. Traditional risk factors like smoking, body mass index,
male gender, age, dyslipidaemia and hypertension play a main
role in the development of CVD, however, continuous inﬂam-
mation and endothelial cell activation play a major part as
well. Metabolic syndrome was more frequently detected inFigure 1 Serum angiopoietin-2 levels in rheumatoid arthritis
patients with and without metabolic syndrome as well as the
control.
DAS-28 = disease activity score in 28 joints, ESR= erythrocyte
sedimentation rate.
* Signiﬁcantly different at p< 0.05.RA patients which puts them at a higher cardiovascular risk
[31].
Angiopoietin-2 is expressed primarily in the vascular
endothelium at sites of vascular remodelling. [32]. It has also
been reported that angiopoietin-2 is a heritable trait associated
with cardiovascular risk factors and related to age, smoking,
systolic blood pressure, hypertension treatment and diabetes
[33].
In the current study the level of angiopoietin-2 was signiﬁ-
cantly higher in RA patients compared to the control. This
result agrees with Westra et al. [34], who measured the serum
levels of VEGF, soluble vascular cell adhesion molecule
(sVCAM)-l and angiopoietin-2 in 176 RA patients and found
that the VEGF and angiopoietin-2 are elevated at the time of
diagnosis. In another study on Egyptian RA patients, serum
angiopoietin-2 was signiﬁcantly higher in patients compared
to the control (p< 0.001) [35]. In this study there is a signiﬁ-
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Figure 3 Correlation between the serum angiopoietin-2 level and
disease activity score (DAS-28) in RA patients.
12 A.H.A.H. Ghazaly et al.compared to those without. Westra et al. [34], also found that
angiopoietin-2 levels increased in RA patients who developed
CVD than those who did not.
In the present study, serum angiopoietin-2 levels signiﬁ-
cantly correlated with fasting blood glucose, blood pressure
and triglycerides. In agreement, the study of Lim. et al. [36],
found that angiopoietin-2, like the VEGF level, is selectively
elevated in patients with diabetes. In another study [37], it
was found that angiopoietin-2 levels increase in hypertensive
patients and they suggested to use it as a biomarker for cardio-
vascular diseases. Furthermore, Anuradha et al. [38] studied
the association of angiopoietin-2 in Asian Indian subjects with
different grades of glucose intolerance and in those with hyper-
tension and MetS and found that there was a linear increase in
mean angiopoietin-2 values with increasing severity of glucose
intolerance, even after adjusting for age, sex, and body mass
index. Angiopoietin-2 levels were also elevated in subjects with
hypertension and with MetS even in the absence of fasting
hyperglycaemia. There was a signiﬁcant correlation of angio-
poietin-2 with the increase in a number of MetS components.
Angiopoietin-2 signiﬁcantly correlated with the disease
activity index (DAS-28) in RA patients and this was in accor-
dance with the work of others [34] indicating a close relation-
ship between angiopoietin-2 and inﬂammation in RA. It has
been shown that the combination of angiopoietin-2 and
TNF-a signiﬁcantly increases cytokine release from synovial
ﬁbroblasts compared to TNF-a alone and it was suggested that
angiopoietin-2 sensitizes synovial cells to activation by TNF-a,
thereby having a direct effect on inﬂammation [39]. Similarly,
in a study on Egyptian RA patients, serum angiopoietin-2 sig-
niﬁcantly correlated with disease activity markers (ESR, CRP),
DAS28 and duration of morning stiffness. It was also sug-
gested that the role of angiopoietin-2 in RA pathogenesis
might open the door to the development of new therapeutic
strategies, particularly those which target angiogenesis [35].
In conclusion, angiopoietin-2 can be used as a marker for
disease activity and metabolic syndrome in RA patients which
can help to detect those at risk of cardiovascular diseases.
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